Raymond Scott Turner

List of Publications by Year
in descending order

95 papers	7,327 citations	57681 46 h-index	62345 84 g-index
104 all docs	104 docs citations	104 times ranked	9980 citing authors

#	Article	IF	Citations
1	Class-based antiretroviral exposure and cognition among women living with HIV (WLWH). AIDS Research and Human Retroviruses, 2022, , .	0.5	0
2	Nilotinib Improves Bioenergetic Profiling in Brain Astroglia in the 3xTg Mouse Model of Alzheimerâ€™s Disease. , 2021, 12, 441.		22
3	Research Attitudes Questionnaire scores predict Alzheimerâ€™s disease clinical trial dropout. Clinical Trials, 2021, 18, 237-244.	0.7	9
4	Acceptability of collecting speech samples from the elderly via the telephone. Digital Health, 2021, 7, 205520762110021.	0.9	6
5	Low CD4+ cell count nadir exacerbates the impacts of APOE Îµ4 on functional connectivity and memory in adults with HIV. Aids, 2021, 35, 727-736.	1.0	14
6	Spatial inhibition of return is impaired in mild cognitive impairment and mild Alzheimerâ€™s disease. PLoS ONE, 2021, 16, e0252958.	1.1	2
7	API generation program: Active immunotherapy CAD106 slows amyloid deposition in cognitively unimpaired APOE4 homozygotes. Alzheimer's and Dementia, 2021, 17, .	0.4	1
8	A 5-min Cognitive Task With Deep Learning Accurately Detects Early Alzheimer's Disease. Frontiers in Aging Neuroscience, 2020, 12, 603179.	1.7	13
9	Nilotinib effects on safety, tolerability, and biomarkers in Alzheimerâ€™s disease: A phase 2, doubleâ€blind, randomized, placeboâ€controlled trial. Alzheimer's and Dementia, 2020, 16, e044628.	0.4	1
10	Potential New Approaches for Diagnosis of Alzheimer's Disease and Related Dementias. Frontiers in Neurology, 2020, 11, 496.	1.1	54
11	Nilotinib Effects on Safety, Tolerability, and Biomarkers in Alzheimer's Disease. Annals of Neurology, 2020, 88, 183-194.	2.8	73
12	Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease. JAMA Neurology, 2019, 76, 1219.	4.5	107
13	Early Detection of Alzheimerâ€™s Disease Using Patient Neuropsychological and Cognitive Data and Machine Learning Techniques. , 2019, , .		18
14	Long-Term maintenance of anomia treatment effects in primary progressive aphasia. Neuropsychological Rehabilitation, 2019, 29, 1439-1463.	1.0	27
15	P3â€016: BASELINE ATTITUDES TOWARD RESEARCH PREDICT LIKELIHOOD OF TRIAL COMPLETION. Alzheimer's and Dementia, 2018, 14, P1068.	0.4	0
16	P2â€495: BEHAVIORAL AND MRI MEASURES SHOW IMPAIRED SPATIAL INHIBITION OF RETURN IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P919.	0.4	0
17	Cancer-Related Cognitive Outcomes Among Older Breast Cancer Survivors in the Thinking and Living With Cancer Study. Journal of Clinical Oncology, 2018, 36, 3211-3222.	0.8	112
18	Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimerâ€™s disease. Journal of Neuroinflammation, 2017, 14, 1.	3.1	544

#	Article	IF	Citations
19	Distinct patterns of increased translocator protein in posterior cortical atrophy and amnestic Alzheimer's disease. Neurobiology of Aging, 2017, 51, 132-140.	1.5	39
20	¹¹ C-PBR28 PET detects translocator protein in a patient with astrocytoma and Alzheimer disease. Neurology, 2017, 88, 1001-1004.	1.5	11
21	Polo-like kinase 2 phosphorylation of amyloid precursor protein regulates activity-dependent amyloidogenic processing. Neuropharmacology, 2017, 117, 387-400.	2.0	21
22	Resveratrol for Alzheimer's disease. Annals of the New York Academy of Sciences, 2017, 1403, 142-149.	1.8	198
23	The BIOCARD Index. Alzheimer Disease and Associated Disorders, 2017, 31, 114-119.	0.6	6
24	[ICâ€Pâ€146]: TASKâ€FREE MAGNETIC RESONANCE BRAIN IMAGING DISTINGUISHES ALZHEIMER's DISEASE FROM HIVâ€DISEASE VIA SUPPORT VECTOR MACHINE CLASSIFICATION. Alzheimer's and Dementia, 2017, 13, P111.	0.4	0
25	[P1â€“373]: TASKâ€FREE MAGNETIC RESONANCE BRAIN IMAGING DISTINGUISHES ALZHEIMER's DISEASE FROM HIVâ€DISEASE VIA SUPPORT VECTOR MACHINE CLASSIFICATION. Alzheimer's and Dementia, 2017, 13, P404.	0.4	0
26	P2-183: An Amyloid Pet-Positive Subject with HIV and Dementia. , 2016, 12, P687-P687.		0
27	11C-PBR28 binding to translocator protein increases with progression of Alzheimer's disease. Neurobiology of Aging, 2016, 44, 53-61.	1.5	135
28	An individual with human immunodeficiency virus, dementia, and central nervous system amyloid deposition. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 4, 1-5.	1.2	48
29	O4â€08â€04: Resveratrol Activates the CNS SIRTUIN1/Matrix Mettaloproteinaseâ€9 Pathway and Regulates Neuroinflammation in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P352.	0.4	1
30	Hexa (ethylene glycol) derivative of benzothiazole aniline promotes dendritic spine formation through the RasGRF1â€“Ras dependent pathway. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 284-295.	1.8	10
31	Nilotinib and bosutinib modulate pre-plaque alterations of blood immune markers and neuro-inflammation in Alzheimerâ€™s disease models. Neuroscience, 2015, 304, 316-327.	1.1	70
32	A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease. Neurology, 2015, 85, 1383-1391.	1.5	511
33	Cognitive Impairment in Older Patients With Breast Cancer Before Systemic Therapy: Is There an Interaction Between Cancer and Comorbidity?. Journal of Clinical Oncology, 2014, 32, 1909-1918.	0.8	129
34	A tetra(ethylene glycol) derivative of benzothiazole aniline ameliorates dendritic spine density and cognitive function in a mouse model of Alzheimer's disease. Experimental Neurology, 2014, 252, 105-113.	2.0	31
35	Cognitive Changes Preceding Clinical Symptom Onset of Mild Cognitive Impairment and Relationship to ApoE Genotype. Current Alzheimer Research, 2014, 11, 773-784.	0.7	108
36	Cognitive Effects of Cancer and Its Treatments at the Intersection of Aging: What Do We Know; What Do We Need to Know?. Seminars in Oncology, 2013, 40, 709-725.	0.8	119

#	Article	IF	Citations
37	Mercaptoacetamide-based class II HDAC inhibitor lowers AÎ² levels and improves learning and memory in a mouse model of Alzheimer's disease. Experimental Neurology, 2013, 239, 192-201.	2.0	117
38	Coexisting adult polyglucosan body disease with frontotemporal lobar degeneration with transactivation response DNA-binding protein-43 (TDP-43)-positive neuronal inclusions. Neurocase, 2013, 19, 67-75.	0.2	6
39	Age-related loss of noradrenergic neurons in the brains of triple transgenic mice. Age, 2013, 35, 139-147.	3.0	43
40	Antihypertensive drug Valsartan promotes dendritic spine density by altering AMPA receptor trafficking. Biochemical and Biophysical Research Communications, 2013, 439, 464-470.	1.0	16
41	Cyclooxygenaseâ€1 inhibition reduces amyloid pathology and improves memory deficits in a mouse model of Alzheimer's disease. Journal of Neurochemistry, 2013, 124, 59-68.	2.1	104
42	In vivo radioligand binding to translocator protein correlates with severity of Alzheimerâ€™s disease. Brain, 2013, 136, 2228-2238.	3.7	280
43	A Tetra(Ethylene Glycol) Derivative of Benzothiazole Aniline Enhances Ras-Mediated Spinogenesis. Journal of Neuroscience, 2013, 33, 9306-9318.	1.7	22
44	Alzheimer disease pathology in cognitively healthy elderly: A genome-wide study. Neurobiology of Aging, 2011, 32, 2113-2122.	1.5	93
45	ApoE Receptor 2 Regulates Synapse and Dendritic Spine Formation. PLoS ONE, 2011, 6, e17203.	1.1	43
46	Decreased dendritic spine density and abnormal spine morphology in Fyn knockout mice. Brain Research, 2011, 1415, 96-102.	1.1	34
47	Temporoparietal Hypometabolism in Frontotemporal Lobar Degeneration and Associated Imaging Diagnostic Errors. Archives of Neurology, 2011, 68, 329-37.	4.9	71
48	Validation of Consensus Panel Diagnosis in Dementia. Archives of Neurology, 2010, 67, 1506-12.	4.9	30
49	ApoE mimetic peptide decreases AÎ² production in vitro and in vivo. Molecular Neurodegeneration, 2010, 5, 16.	4.4	22
50	The cytoplasmic adaptor protein X11Î± and extracellular matrix protein Reelin regulate ApoE receptor 2 trafficking and cell movement. FASEB Journal, 2010, 24, 58-69.	0.2	26
51	Therapeutic versus neuroinflammatory effects of passive immunization is dependent on AÎ²/amyloid burden in a transgenic mouse model of Alzheimer's disease. Journal of Neuroinflammation, 2010, 7, 57.	3.1	18
52	Beta amyloid-independent role of amyloid precursor protein in generation and maintenance of dendritic spines. Neuroscience, 2010, 169, 344-356.	1.1	109
53	X11Î± haploinsufficiency enhances AÎ² amyloid deposition in Alzheimer's disease transgenic mice. Neurobiology of Disease, 2009, 36, 162-168.	2.1	19
54	Amyloid-Î²-Induced Ion Flux in Artificial Lipid Bilayers and Neuronal Cells: Resolving a Controversy. Neurotoxicity Research, 2009, 16, 1-13.	1.3	99

#	Article	IF	Citations
55	ApoE4 Decreases Spine Density and Dendritic Complexity in Cortical NeuronsIn Vivo. Journal of Neuroscience, 2009, 29, 15317-15322.	1.7	195
56	FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain, 2007, 130, 2616-2635.	3.7	508
57	Alzheimer's Disease. Seminars in Neurology, 2006, 26, 499-506.	0.5	50
58	A comparison of classification methods for differentiating fronto-temporal dementia from Alzheimer's disease using FDG-PET imaging. Statistics in Medicine, 2004, 23, 315-326.	0.8	87
59	X11Î± impairs Î³â€•but not Î²â€cleavage of amyloid precursor protein. Journal of Neurochemistry, 2004, 88, 971-982.	2.1	35
60	Adaptor protein interactions: modulators of amyloid precursor protein metabolism and Alzheimer's disease risk?. Experimental Neurology, 2004, 185, 208-219.	2.0	135
61	Biomarkers of alzheimerâ€™s disease and mild cognitive impairment: are we there yet?. Experimental Neurology, 2003, 183, 7-10.	2.0	27
62	X11Î± modulates secretory and endocytic trafficking and metabolism of amyloid precursor protein: mutational analysis of the yenpty sequence. Neuroscience, 2003, 120, 143-154.	1.1	55
63	Synergistic Effects of Munc18a and X11 Proteins on Amyloid Precursor Protein Metabolism. Journal of Biological Chemistry, 2002, 277, 27021-27028.	1.6	47
64	Idiopathic Rapid Eye Movement Sleep Behavior Disorder Is a Harbinger of Dementia with Lewy Bodies. Journal of Geriatric Psychiatry and Neurology, 2002, 15, 195-199.	1.2	46
65	Overexpression of hAPPswe Impairs Rewarded Alternation and Contextual Fear Conditioning in a Transgenic Mouse Model of Alzheimer's Disease. Learning and Memory, 2002, 9, 243-252.	0.5	121
66	Spontaneous intracranial hypotension causing reversible frontotemporal dementia. Neurology, 2002, 58, 1285-1287.	1.5	126
67	Inherited dementias. Neurologic Clinics, 2002, 20, 779-808.	0.8	12
68	ELISA analysis of beta-secretase cleavage of the Swedish amyloid precursor protein in the secretory and endocytic pathways. Journal of Neurochemistry, 2002, 80, 1019-1028.	2.1	26
69	Alzheimerâ€™s Disease in Man and Transgenic Mice. American Journal of Pathology, 2001, 158, 797-801.	1.9	32
70	Differentiated Human NT2-N Neurons Possess a High Intracellular Content of myo-Inositol. Journal of Neurochemistry, 2001, 72, 1431-1440.	2.1	48
71	The Protease Inhibitor, MG132, Blocks Maturation of the Amyloid Precursor Protein Swedish Mutant Preventing Cleavage by Î²-Secretase. Journal of Biological Chemistry, 2001, 276, 4476-4484.	1.6	64
72	The pathology of REM sleep behavior disorder with comorbid Lewy body dementia. Neurology, 2000, 55, 1730-1732.	1.5	104

#	Article	IF	Citations
73	FORUM What Persian Gulf War Syndrome?. Clinical Neuropsychologist, 2000, 14, 341-343.	1.5	6
74	Modulation of Amyloid Precursor Protein Metabolism by X11Î±/Mint-1. Journal of Biological Chemistry, 2000, 275, 39302-39306.	1.6	55
75	Molecular Analysis of the X11â€“mLin-2/CASK Complex in Brain. Journal of Neuroscience, 1999, 19, 1307-1316.	1.7	92
76	The X11Î± Protein Slows Cellular Amyloid Precursor Protein Processing and Reduces AÎ²40 and AÎ²42 Secretion. Journal of Biological Chemistry, 1998, 273, 14761-14766.	1.6	183
77	X11 Interaction with Î²-Amyloid Precursor Protein Modulates Its Cellular Stabilization and Reduces Amyloid Î²-Protein Secretion. Journal of Biological Chemistry, 1998, 273, 22351-22357.	1.6	131
78	The Chaperone BiP/GRP78 Binds to Amyloid Precursor Protein and Decreases AÎ²40 and AÎ²42 Secretion. Journal of Biological Chemistry, 1998, 273, 25552-25555.	1.6	163
79	Identification of an Evolutionarily Conserved Heterotrimeric Protein Complex Involved in Protein Targeting. Journal of Biological Chemistry, 1998, 273, 31633-31636.	1.6	175
80	Probable diffuse Lewy body disease presenting as REM sleep behavior disorder. Neurology, 1997, 49, 523-527.	1.5	75
81	Clinical, neuroimaging, and pathologic features of progressive nonfluent aphasia. Annals of Neurology, 1996, 39, 166-173.	2.8	157
82	Vaccinia virus serves as an efficient vector for expressing heterologous proteins in human NTera 2 neurons. , 1996, 374, 481-492.		7
83	Amyloids and Are Generated Intracellularly in Cultured Human Neurons and Their Secretion Increases with Maturation. Journal of Biological Chemistry, 1996, 271, 8966-8970.	1.6	154
84	Human neurons derived from a teratocarcinoma cell line express solely the 695-amino acid amyloid precursor protein and produce intracellular beta-amyloid or A4 peptides.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9513-9517.	3.3	216
85	Synthetic myelin basic protein peptide analogs are specific inhibitors of phospholipid/calcium-dependent protein kinase (protein kinase C). Biochemical and Biophysical Research Communications, 1986, 134, 78-84.	1.0	22
86	Phospholipid/calcium-dependent protein kinase (protein kinase C) system: A major site of bioregulation. Advances in Enzyme Regulation, 1986, 25, 387-392.	2.9	16
87	S-100 and Other Acidic Proteins Promote Ca2+-Independent Phosphorylation of Protamine Catalyzed by a New Protein Kinase from Brain. Journal of Neurochemistry, 1984, 42, 458-465.	2.1	21
88	Phospholipid-Sensitive Ca2+-Dependent Protein Kinase Preferentially Phosphorylates Serine-115 of Bovine Myelin Basic Protein. Journal of Neurochemistry, 1984, 43, 1257-1264.	2.1	59
89	Phospholipid-sensitive Ca2+-dependent protein kinase: a major protein phosphorylation system. Molecular and Cellular Endocrinology, 1984, 35, 65-73.	1.6	122
90	Phospholipid-sensitive Ca2+-dependent protein kinase inhibition by R-24571, A calmodulin antagonist. Biochemical Pharmacology, 1984, 33, 125-130.	2.0	62

#	Article	IF	Citations
91	Developmental studies of phospholipid-sensitive Ca2+-dependent protein kinase and its substrates and of phosphoprotein phosphatases in rat brain.. Proceedings of the National Academy of Sciences of the United States of America, 1984, 81, 3143-3147.	3.3	64
92	Comparative abilities of lanthanide ions La3+ and Tb3+ to substitute for Ca2+ in regulating phospholipid-sensitive Ca2+-dependent protein kinase and myosin light chain kinase. Life Sciences, 1983, 33, 119-129.	2.0	14
93	Cobra polypeptide cytotoxin I and marine worm polypeptide cytotoxin A-IV are potent and selective inhibitors of phospholipid-sensitive Ca2+-dependent protein kinase. FEBS Letters, 1983, 153, 183-186.	1.3	94
94	Basic Protein in Brain Myelin Is Phosphorylated by Endogenous Phospholipid-Sensitive Ca2+-Dependent Protein Kinase. Journal of Neurochemistry, 1982, 39, 1397-1404.	2.1	118
95	Methionine-enkephalin and morphine: Amount ejected microiontophoretically. Journal of Neuroscience Methods, 1981, 4, 135-139.	1.3	5